HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing Pressures 'Manageable' To P&G, But Threatening To Analysts

This article was originally published in The Pink Sheet

Executive Summary

Procter & Gamble says retailer pressure for the firm to lower product pricing to compete with e-commerce and private label is a “real but manageable” problem, while an industry consultant says four megatrends are dictating product prices and changing the way consumers think about consumer health products.

You may also be interested in...



P&G Board Seat Swings To Peltz In Ongoing Vote Tally

P&G says results from an independent tabulator indicate Trian Fund head Nelson Peltz is leading the firm's candidate, Ernesto Zedillo, in a board proxy vote by around 42,780 shares, or 0.0016% of total outstanding shares. But P&G says the vote count isn't completed.

Perrigo's Next Private Label First Lands With Second Thoughts On Outlook

The launch of a private label version 24HR OTC heartburn treatment comes with Perrigo in need of another high-selling product to boost revenues in its core business, OTC private label. But analysts call for Perrigo to do more to grow in new markets.

Ahead Of P&G Board Vote, Activist Investor Peltz Gains Endorsements

As Procter & Gamble prepares for a shareholder vote that could shake up its board and its strategies, proxy advisor Glass, Lewis & Co. recommends shareholders vote in favor of electing Trian Fund Management CEO Nelson Peltz, who's pressing the firm for dramatic operational changes.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS122774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel